SAN DIEGO--(BUSINESS WIRE)--Seqster PDM, Inc. ('SEQSTER'), the leading healthcare technology company, today announced CEO and Co-Founder Ardy Arianpour has been named to the prestigious 2023 PharmaVoice 100, a recognition of the 100 most inspiring people in the life sciences industry.

今天领先的医疗保健技术公司圣地亚哥-（商业线）-Seqster PDM，Inc。（'Seqster'）宣布首席执行官兼联合创始人Ardy Arianpour已被授予负盛誉的2023 PharmaVoice 100，生命科学行业100个最鼓舞人心的人。

Arianpour joins a diverse group of industry leaders who were selected based on their inspirational qualities as well as their ability to innovate, develop breakthrough strategies, and improve the lives of patients. This year’s honorees include: Standout execs, Trailblazers, Cancer care visionaries, Clinical trial gurus, Patient heroes, Entrepreneurs, Tech wizards, Rare disease warriors, and Brand and commercialization pros..

Arianpour加入了各种各样的行业领导者，他们根据自己的灵感品质以及创新，制定突破策略和改善患者生活的能力而被选中。今年的荣誉包括：脱颖而出的执行者，开拓者，癌症护理愿景，临床试验人物，患者英雄，企业家，技术向导，罕见疾病战士以及品牌和商业化专业人士。。

PharmaVoice recognized Arianpour for his visionary leadership, entrepreneurial spirit, and ability to build and execute an innovative patient-centric data technology company that is revolutionizing drug development by connecting patients and their real-time real-world data directly with researchers.

PharmaVoice认可Arianpour具有远见的领导力，创业精神，能够建立和执行创新的以患者为中心的数据技术公司，该公司通过将患者及其实时实时数据直接与研究人员联系起来，彻底改变药物开发。

Under his leadership, SEQSTER has built an operating system that connects patients, researchers, sponsors and clinical trial sites together to accelerate drug development..

在他的领导下，SEQSTER建立了一个操作系统，将患者，研究人员，赞助商和临床试验场所连接在一起，以加速药物开发。。

'I am deeply honored to be recognized for the PharmaVoice 100. My mission has always been to place the patient at the center of all their health data, breaking down data silos and transforming clinical research. Our operating system, which includes a digital front door for patients and researchers, has become the preferred technology solution driving real-time Real World Data connectivity, data refinement, and patient engagement for leading life sciences companies such as Boehringer Ingelheim, Takeda, UBC (United BioSource), and national patient registries such as the National Pancreas Foundation (NPF),' stated Ardy Arianpour..

“我非常荣幸因PharmaVoice 100而获得认可。我的使命一直是将患者置于所有健康数据的中心，分解数据仓库并改变临床研究。我们的操作系统包括患者和研究人员的数字前门，已成为推动领先生命科学公司（如勃林格殷格翰，武田，UBC）的实时现实世界数据连接，数据改进和患者参与的首选技术解决方案。（United BioSource）和国家患者登记处，如国家胰腺基金会（NPF），'Ardy Arianpour说。。

Throughout a distinguished 20-year career in the life sciences sector, Ardy Arianpour has consistently demonstrated a relentless dedication to driving innovation and introducing disruptive products for both patients and researchers. Prior to founding SEQSTER, Arianpour had the privilege of launching various clinical and consumer-based genetic tests while serving as Senior Vice President and General Manager of Genomics at Ambry Genetics, a company that was acquired by Konica for $1 billion in 2017.

在生命科学领域的20年杰出职业生涯中，Ardy Arianpour一直表现出不懈的奉献精神，致力于推动创新并为患者和研究人员引入颠覆性产品。在成立SEQSTER之前，Arianpour有特权发起各种基于临床和消费者的基因测试，同时担任Ambry Genetics的高级副总裁和基因组学总经理，该公司于2017年被Konica收购10亿美元。

One of Arianpour’s significant contributions was his pivotal role in the landmark 2013 SCOTUS decision that eliminated gene patents, democratizing access to genetic testing. The introduction of BRCA testing, in particular, had a profound impact on patients, caregivers and their families nationwide..

Arianpour的重要贡献之一是他在2013年苏格兰具有里程碑意义的决定中的关键作用，该决定取消了基因专利，使基因检测的民主化。特别是引入BRCA测试，对全国范围内的患者，护理人员及其家人产生了深远的影响。。

Arianpour has been widely recognized globally as a pioneer in healthcare with many awards, such as the American Heart Association Health Tech Award 2018, Top 40 Healthcare Transformer by Medical, Marketing, and Media (MM&M 2019), San Diego Business Journal's 40 Under 40 in 2019, Top Tech Awards in 2021, Top 10 Pioneers Redefining Healthcare in 2021 and Med Tech World Rising Star 2022..

Arianpour已被全球广泛认可为医疗保健领域的先驱，获得多项奖项，例如2018年美国心脏协会健康技术奖，医疗，营销和媒体排名前40位的医疗保健变压器（MM＆M 2019），圣地亚哥商业杂志40岁以下2019年获得Top Tech奖，2021年获得Top Tech奖，2021年获得Top 10先驱重新定义医疗保健，2022年获得Med Tech World新星。。

Since 2005, the PharmaVoice 100 has become one of the publication’s most anticipated features. PharmaVoice developed the only awards program in the industry to recognize individuals of all ages representing all sectors of the life sciences industry — from academia to nonprofit organizations to big pharma to emerging biotech companies to technology companies to commercial organizations that provide molecule-to-market services in support of moving the needle to benefit patients around the world.

自2005年以来，PharmaVoice 100已成为该出版物最具预期的特色之一。PharmaVoice制定了该行业唯一的奖项计划，以认可代表生命科学行业所有部门的各个年龄段的个人-从学术界到非营利组织，大制药到新兴生物技术公司，再到技术公司到提供分子到市场的商业组织服务，以支持移动针头使患者受益世界。

The PharmaVoice 100 continues to contain a diverse mix of people across a range of disciplines — from the clinic to the C-suite — who are making meaningful contributions in their fields of influence..

PharmaVoice 100继续包含来自各个学科（从诊所到C-suite）的各种各样的人员，他们正在其影响领域做出有意义的贡献。。

Arianpour will be presenting how SEQSTER powers pragmatic clinical trials with their newest partner, Optum Life Sciences, at DPHARM Conference - Disruptive Innovations to Modernize Clinical Research, September 21, 2023 at the Westin Copley Conference Center in Boston.

Arianpour将于2023年9月21日在波士顿的Westin-Copley会议中心在DPHARM会议-颠覆性创新以实现临床研究现代化方面展示SEQSTER如何与其最新合作伙伴Optum Life Sciences一起为实用临床试验提供动力。

PharmaVoice will recognize this year's honorees at the 2023 PharmaVoice 100 Exclusive Event: “The NextFrontier of the Life Sciences” on Oct. 25-26. Hosted by award-winning journalists, this event will feature a range of keynotes, panel discussions and fireside chats on the critical trends facing the industry including innovation, genetic medicine, research hot spots, the biotech market, clinical trial tech advancements and more..

PharmaVoice将于2023年PharmaVoice 100独家活动“生命科学的下一个前沿”于10月25日至26日表彰今年的荣誉。本次活动由获奖的记者主持，将针对行业面临的关键趋势，包括创新，遗传医学，研究热点，生物技术市场，临床试验技术进步等进行一系列主题演讲，小组讨论和fireside聊天。。

About SEQSTER

关于SEQSTER

SEQSTER is the leading healthcare technology company that breaks down health data silos at scale. Its enterprise operating system aggregates disparate health data sources into a single, 360-degree view of a patient in real-time, solving a multitude of challenges for life sciences, patient engagement and data interoperability..

SEQSTER是领先的医疗技术公司，可以大规模分解健康数据仓库。其企业操作系统将不同的健康数据源实时汇总到患者的单一360度视图中，解决了生命科学，患者参与和数据互操作性方面的诸多挑战。。

SEQSTER has nationwide coverage of EHRs from hospitals and medical groups, genomic DNA, wearables, pharmacy and social determinants of health data. Through its customizable white-label approach, SEQSTER provides accelerated access to de-identified, tokenized, real-time data and comprehensive curated data to address critical needs across the healthcare continuum..

SEQSTER在全国范围内覆盖来自医院和医疗团体的EHR，基因组DNA，可穿戴设备，药房和健康数据的社会决定因素。通过其可定制的白色标签方法，SEQSTER提供了对去识别，标记化，实时数据和全面策划数据的加速访问，以满足整个医疗保健连续体的关键需求。。

SEQSTER is privately held and headquartered in San Diego.

SEQSTER是私营公司，总部设在圣地亚哥。

To learn more about the Seqster Operating System for Clinical Studies, Patient Registries and the Digital Front Door, please contact us at info@seqster.com or visit www.seqster.com.

要了解有关用于临床研究的Seqster操作系统，患者注册表和数字前门的更多信息，请与我们联系info@seqster.com或访问www.seqster.com。

About PharmaVoice

关于PharmaVoice

PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.

PharmaVoice是由industry Dive运营的领先行业出版物。我们的故事将生命科学中最重要的声音和想法传达给行业领导者。

About Industry Dive

关于工业潜水

Industry Dive, an Informa business, is a leading business journalism company. Over 14 million decision-makers across 20+ competitive industries rely on our exclusive insight and analysis delivered through more than 30 publications.

Industry Dive是一家Informa业务，是一家领先的商业新闻公司。20多个竞争行业的1400多万决策者依靠我们通过30多个出版物提供的独家见解和分析。